Intelligence workspace
Reimbursement context, historical acquirer-profile overlap, and export tools. Overlap indexes are descriptive heuristics — they do not feed deal economics, valuation peers, or dual-source badges.
System Health & Monitoring
Live API checks plus the measurement-layer census: quality grades, withheld metrics, vintage gaps, and display provenance.
Data Pipeline Status
Counts and grades from verified artifacts — no fabricated latency or invented completion percentages.
Dataset version v11. Grades and coverage come from computed-data-quality-scores.json and provenance-baseline.json, hash-verified on every push. SEC ingest uses live loadSummaryPipelines when LACUNA_DATA_MODE=db.
Measurement layer
Quality grades, gated-metric publication, vintage gaps, and display provenance — read from computed artifacts, not a hardcoded pipeline panel.
Company source quality
avg
Deal source quality
avg
44/98 active economic records. 31 are current-only because publicAsOfDate is missing (totalFunding 22/40, lastKnownValuation 9/58). Missing dates stay missing.
/47 computedPremium rows exactly reproducible · Deal values use announcement date only (52/52) — not a value vintage. · Pre-deal valuations with date: 49/49.
Most uncovered numeric render files
- src/components/WhiteSpaceAnalysis.tsx86
- src/components/NetworkAnalysisHonest.tsx83
- src/components/StrategicPositioningMap.tsx61
- src/app/sections/PayerOpsPage.tsx49
- src/components/FairnessAuditV2.tsx46
- src/components/CompetitiveAnalysisDashboard.tsx33
- src/components/FounderCharacteristics.tsx33
- src/components/GenderInferenceQuality.tsx26
Artifact v11 · hash 5a0a432d5db8 · 2026-10-19T00:00:00.000Z · 66 companies and 5 deals graded D/F
Reimbursement & Commercial Due Diligence
Verified deal context by sector from the curated dataset — no invented TAM, payer mix, or keyword risk scores. The SA051 card is an investigation target, not a payment conclusion.
Catalyst watchlist
Weekly biopharma calendar joined to Lacuna's verified acquirer and company ids. Dates are scheduled PDUFA/readout marks with an actual date when the decision already happened.
Women's-health relevant
12 of 85 weekly catalysts are tagged women's-health relevant. The current feed is general biopharma; Lacuna IDs are filled only when the company is already in the verified universe.
| Scheduled | Company | Event | Status | Basis |
|---|---|---|---|---|
| 2026-09-04actual 2026-09-04 | AstraZenecaEtcamah (camizestrant) | approvalESR1-mutated HR+/HER2- advanced or metastatic breast cancer | approved | actual_event · dayBreast HealthNCT04964934 |
| 2026-09-10actual 2026-09-10 | AbbVieatogepant (QULIPTA/AQUIPTA) | readoutpreventive treatment of menstrual migraine | positive | actual_event · dayTherapeutics |
| 2026-09-17actual 2026-09-17 | Biosimilar Collaborations Irelandpertuzumab biosimilar (Pebrilzo) | CHMPHER2-positive early and metastatic breast cancer | positive | actual_event · dayBreast Health |
| 2026-09-17actual 2026-09-17 | Corcept Therapeuticsrelacorilant (Lifyorli) | CHMPplatinum-resistant high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer, with nab-paclitaxel | positive | actual_event · dayTherapeuticsNCT05257408 |
| 2026-09-17actual 2026-09-17 | SFL Pharmaceuticals Deutschlandsenaparib (Sepalna) | CHMPmaintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer | positive | actual_event · dayTherapeutics |
| 2026-09-25actual 2026-09-25 | SimBioSysTumorSight Risk (510(k)) | approval5- and 10-year recurrence risk, HR+/HER2- stage I-IIIA breast cancer | approved | actual_event · dayBreast Health |
| 2026-10-07actual 2026-10-07 | PfizerTukysa (tucatinib)Seagen → Pfizer | approvalHER2+ metastatic breast cancer, first-line maintenance with trastuzumab and pertuzumab (HER2CLIMB-05) | approved | actual_event · dayacquirer-pfizer · Breast HealthNCT05132582 |
| 2026-10-15actual 2026-10-15 | PfizerTukysa (tucatinib) extensionSeagen → Pfizer | CHMPmaintenance with trastuzumab + pertuzumab in HER2+ unresectable/metastatic breast cancer after 1L induction | positive | actual_event · dayacquirer-pfizer · Breast HealthNCT05132582 |
| 2026-11-30 | Rochegiredestrant (adjuvant) | PDUFAER+/HER2- stage I-III early breast cancer (lidERA) | upcoming | third_party_calendar · dayacquirer-roche · Breast HealthNCT04961996 |
| 2026-12-18 | Rochegiredestrant + everolimus | PDUFAESR1-mutated ER+/HER2- advanced breast cancer (evERA) | upcoming | third_party_calendar · dayacquirer-roche · Breast HealthNCT05306340 |
| 2027-04-01 | BayerLynkuet (elinzanetant) sNDAKaNDy Therapeutics → Bayer | PDUFAvasomotor symptoms from endocrine therapy for HR+ breast cancer (OASIS-4) | upcoming | estimated · quarteracquirer-bayer · MenopauseNCT05587296 |
| 2027-04-01 | Organon/Sebela Women's HealthMIUDELLA (copper intrauterine system) | PDUFAprevention of pregnancy - extension of duration of use to 6 years | upcoming | company_guidance · quarteracquirer-organon · Contraception |
Tracked acquirers / companies · next 90 days
2 scheduled events in 2026-11-19 → 2027-02-17 for Roche, J&J, GRAIL, or another verified id.
| Scheduled | Company | Event | Status | Basis |
|---|---|---|---|---|
| 2026-11-30 | Rochegiredestrant (adjuvant) | PDUFAER+/HER2- stage I-III early breast cancer (lidERA) | upcoming | third_party_calendar · dayacquirer-roche · Breast HealthNCT04961996 |
| 2026-12-18 | Rochegiredestrant + everolimus | PDUFAESR1-mutated ER+/HER2- advanced breast cancer (evERA) | upcoming | third_party_calendar · dayacquirer-roche · Breast HealthNCT05306340 |
Acquirer Fit & Precedent Map
Verified acquirer profiles and same-sector historical deals beside a company. Historical exits are not an acquisition prediction, and a missing price is not zero.
Export & share
Download the verified dataset in JSON, CSV, or Parquet.
Developer Tools
API documentation, SDK references, code examples, and integration guides for engineers building on the Lacuna platform.